Osimertinib as First-Line Treatment for EGFR Mutation-Positive Advanced NSCLC? (BMIC-017)

Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLCПодробнее

Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLCПодробнее

Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated resultsПодробнее

Dr. Ramalingam on the Role of Osimertinib in eGFR T790M-Positive Advanced NSCLCПодробнее

Osimertinib as Frontline Therapy for EGFR-Positive NSCLCПодробнее

Should a Third Generation EGFR Inhibitor be First Line Therapy for EGFR Mutation-Positive NSCLC?Подробнее

FLAURA final analysis: osimertinib for first-line EGFRm NSCLCПодробнее

Early Returns on FLAURA Trial: Osimertinib as First Line Agent in EGFR Mut-Pos. NSCLC? (BMIC-002)Подробнее

First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and safety in the rea...Подробнее

Osimertinib For Uncommon EGFR Mutations in NSCLCПодробнее

Dr. Wakelee on Benefits of Osimertinib in EGFR-Mutant NSCLC TreatmentПодробнее

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positi...Подробнее

Osimertinib + ipilimumab in EGFR-mutated NSCLCПодробнее

The FLAURA Trial: Practice-Changing Results for EGFR Mutation-Positive NSCLC (BMIC-007)Подробнее

Emerging treatment strategies in EGFR-mutant NSCLC: osimertinib combinations and beyondПодробнее

Osimertinib with Chemotherapy in EGFR-Mutated NSCLC | NEJMПодробнее

Dacomitinib: Dark Horse EGFR TKI Charges into First Line Setting for Advanced NSCLC (BMIC-016)Подробнее

Osimertinib: A potential new standard of care for advanced EGFR-mutated NSCLC | Suresh RamalingamПодробнее

Copy of Dr. West on FDA Approval of Frontline Osimertinib in EGFR+ NSCLCПодробнее